Palestine R F, Millns J L, Spigel G T, Schroeter A L
J Am Acad Dermatol. 1980 Jan;2(1):47-55. doi: 10.1016/s0190-9622(80)80292-1.
Seventeen patients who had cutaneous complications following pentazocine injections are presented. The mean age was 50 years; total daily pentazocine dose ranged from 60 to 2,400 mg; evidence of psychiatric illness was present in 94%, and previous drug or alcohol abuse was noted in 65%. Fifty-three percent of our series of patients had a medical or paramedical background. Eighteen percent had diabetes mellitus, and 65% had a personal or family history (or both) of diabetes. A hypothesis is presented for this association. Characteristic histologic findings included fibrosis of the dermis and panniculus, with vascular alterations, fat necrosis with granulomatous inflammation, and vascular thrombosis with occasional endarteritis. We emphasize that medical and paramedical personnel and patients with a personal or family history of diabetes should be added to the group of patients considered to be at special risk for cutaneous complications of pentazocine injections.
本文报告了17例喷他佐辛注射后出现皮肤并发症的患者。平均年龄为50岁；喷他佐辛每日总剂量为60至2400毫克；94%的患者有精神疾病证据，65%的患者有既往药物或酒精滥用史。我们的患者系列中有53%具有医学或准医学背景。18%的患者患有糖尿病，65%的患者有个人或家族糖尿病史（或两者皆有）。本文提出了关于这种关联的一种假说。特征性组织学表现包括真皮和 panniculus 的纤维化、血管改变、伴有肉芽肿性炎症的脂肪坏死以及伴有偶发性动脉内膜炎的血管血栓形成。我们强调，应将医学和准医学人员以及有个人或家族糖尿病史的患者纳入被认为有喷他佐辛注射皮肤并发症特殊风险的患者群体中。
